SynthesisFrontiers in pharmacology2025

Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: An updated systematic review and meta-analysis.

Ying Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.